-Reuters
Acumen Pharma’s Stock Doubles In One Session – Here’s Why
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) presented topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomers (AβO) targeting antibody therapy in early AD, at the Alzheimer's Association